Head-to-head evidence
Ongericimab vs RBD7022
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ongericimab · Junshida
Developed by Shanghai Junshi Bioscience
NCT04781114 · Phase 3 · completed
This large, randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint was clearly met: both ongericimab dose regimens produced large, statistically significant reductions in LDL cholesterol versus placebo.
RBD7022
Developed by Suzhou Ribo Life Science
NCT05912296 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ongericimab's landscape · RBD7022's landscape